Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03219593 | Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03937830 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 |
| Sep 8, 2026 |
| clinicaltrials |
| NCT04107077 | Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer | recruiting | Phase 2 | 21 | University of ChicagoOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04207944 | The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) | active not recruiting | Phase 2 | 100 | Duke UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06861452 | Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma(SNIPER) | recruiting | Phase 1 / Phase 2 | 9 | EIR Biotherapies s.r.l.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07779694 | 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer | not yet recruiting | Phase 2 | 51 | Zhejiang UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806110 | Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer | active not recruiting | Phase 2 | 62 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806292 | Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study(ABH-uHCC) | recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807800 | A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 1 / Phase 2 | 88 | D. E. Shaw Research, LLCINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | not yet recruiting | Phase 2 | 100 | Solstice Oncology, Inc.INDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT01591733 | FOLFIRINOX + RT for Pancreatic Cancer | completed | Phase 2 | 48 | Massachusetts General HospitalOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01972919 | MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer | completed | Phase 2 | 23 | Medical College of WisconsinOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03608631 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | suspended | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06390059 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 84 | NovoCure Ltd.INDUSTRY | 4 | Sep 4, 2026 | clinicaltrials |
| NCT06526338 | Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone | recruiting | Phase 2 | 315 | Robert C. MartinOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07062055 | BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases | recruiting | Phase 2 | 54 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 220 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04069273 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma(SEQUEL) | active not recruiting | Phase 2 | 58 | Harry H YoonOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04493060 | Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | completed | Phase 2 | 22 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04524871 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)(MORPHEUS-LIVER) | active not recruiting | Phase 1 / Phase 2 | 518 | Hoffmann-La RocheINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT05167409 | Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | terminated | Phase 2 | 19 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | recruiting | Phase 2 | 146 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | recruiting | Phase 1 / Phase 2 | 210 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 3, 2026 | clinicaltrials |
| NCT06811116 | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | recruiting | Phase 2 | 180 | Verastem, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801352 | CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802184 | GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC | not yet recruiting | Phase 1 / Phase 2 | 45 | West China HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802418 | Molecularly Tailored Therapy in Advanced Pancreatic Cancer(TAILOR-PANC) | not yet recruiting | Phase 2 | 1,200 | Herlev HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02794428 | Chemoprevention of Gastric Carcinogenesis | completed | Phase 2 | 91 | Vanderbilt-Ingram Cancer CenterOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT04276493 | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | completed | Phase 1 / Phase 2 | 71 | BeiGeneINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT04749108 | Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma(GRECCAR14) | recruiting | Phase 2 / Phase 3 | 1,075 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05247905 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | active not recruiting | Phase 2 | 31 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05585814 | CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer(COBP) | active not recruiting | Phase 2 | 30 | Shanghai Changzheng HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 2, 2026 | clinicaltrials |
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | recruiting | Phase 2 | 38 | Mehmet AkceOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06855225 | A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma | not yet recruiting | Phase 2 | 29 | Mehmet AkceOTHER | 1 | Sep 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials